- Conditions
- Breast Cancer, Depression, Fatigue
- Interventions
- Bio-field energy therapy, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment, therapeutic touch
- Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years to 75 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 7,077
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Carcinoma, Cancer Survivor, Cervical Carcinoma, Dyspareunia, Vaginal Dryness
- Interventions
- Laser Therapy, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer, BRCA Mutation
- Interventions
- Tranexamic acid, Normal saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
- Interventions
- Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing
- Drug · Diagnostic Test
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer, Cancer of Breast, Cancer of the Breast
- Interventions
- Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw
- Procedure · Behavioral · Device + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer, Head and Neck Cancer
- Interventions
- Palbociclib, Cetuximab, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Early Breast Cancer
- Interventions
- PF-05280014, Taxotere®, Paraplatin®, Trastuzumab-EU
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Kingwood, Texas • Shenandoah, Texas
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Renal Cell Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- AFP464, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
- Interventions
- NM32-2668
- Biological
- Lead sponsor
- Numab Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
- Conditions
- Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer, HER2-negative Breast Cancer
- Interventions
- No drug
- Other
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 927 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Liposuction, Quality of Life Questionnaires
- Procedure · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- TNBC - Triple-Negative Breast Cancer, Breast Cancer
- Interventions
- Pembrolizumab, Radiation Therapy, Axatilimab
- Drug · Radiation
- Lead sponsor
- Stephen Shiao
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- therapeutic conventional surgery, whole breast irradiation
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 350
- States / cities
- Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Treatment suggestion
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
- Interventions
- Paclitaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
- Drug · Other
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 890 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
- Conditions
- Breast Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Prostate Cancer, Bladder Cancer
- Interventions
- Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 65 Years to 111 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- RAD001, Carboplatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- LY3484356
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- HER2-normal
- Interventions
- eribulin mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • New York, New York
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
- Interventions
- LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 42
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Springdale, Arkansas + 31 more
- Conditions
- Breast Cancer
- Interventions
- Proton Accelerated Partial Breast Irradiation
- Radiation
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 50 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
- Conditions
- Invasive Breast Cancer Early Stages, Ductal Carcinoma In Situ, DCIS
- Interventions
- VENUS SHELL™ immobilization device
- Device
- Lead sponsor
- HeroSupport SA
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York